bluebird bio (NASDAQ:BLUE) Now Covered by Analysts at StockNews.com

StockNews.com began coverage on shares of bluebird bio (NASDAQ:BLUE) in a report released on Monday morning. The brokerage issued a sell rating on the biotechnology company’s stock.

Several other equities research analysts have also recently weighed in on the company. Barclays cut their target price on bluebird bio from $4.00 to $2.00 and set an “overweight” rating for the company in a research note on Friday. Cantor Fitzgerald restated a “neutral” rating on shares of bluebird bio in a research report on Monday, September 16th. JPMorgan Chase & Co. lowered bluebird bio from a “neutral” rating to an “underweight” rating in a research note on Friday. Bank of America downgraded bluebird bio from a “buy” rating to a “neutral” rating and lowered their target price for the stock from $3.00 to $0.50 in a research note on Friday. Finally, Royal Bank of Canada reaffirmed a “sector perform” rating and set a $4.00 price target on shares of bluebird bio in a report on Friday. Three investment analysts have rated the stock with a sell rating, seven have given a hold rating and two have given a buy rating to the company. According to MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $3.03.

bluebird bio Stock Up 3.8 %

BLUE stock opened at $0.33 on Monday. bluebird bio has a 52 week low of $0.32 and a 52 week high of $5.53. The business has a 50-day simple moving average of $0.49 and a 200 day simple moving average of $0.78. The company has a quick ratio of 0.57, a current ratio of 0.68 and a debt-to-equity ratio of 0.37. The company has a market cap of $64.57 million, a PE ratio of -0.18 and a beta of 0.76.

bluebird bio (NASDAQ:BLUE) last released its earnings results on Friday, September 13th. The biotechnology company reported ($0.36) EPS for the quarter. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 238.15%. The firm had revenue of $18.57 million during the quarter. Sell-side analysts anticipate that bluebird bio will post -1.41 EPS for the current fiscal year.

Institutional Trading of bluebird bio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Geode Capital Management LLC grew its position in shares of bluebird bio by 3.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after buying an additional 166,771 shares during the last quarter. Barclays PLC boosted its holdings in bluebird bio by 273.7% in the third quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after acquiring an additional 184,605 shares during the last quarter. State Street Corp increased its position in bluebird bio by 1.1% during the 3rd quarter. State Street Corp now owns 3,841,923 shares of the biotechnology company’s stock valued at $1,996,000 after purchasing an additional 43,382 shares during the period. Verition Fund Management LLC bought a new position in bluebird bio during the 3rd quarter worth approximately $42,000. Finally, Captrust Financial Advisors lifted its position in shares of bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares during the period. 87.43% of the stock is currently owned by institutional investors and hedge funds.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.